Allogene Therapeutics (ALLO) Other Non-Current Assets (2018 - 2026)

Allogene Therapeutics has disclosed Other Non-Current Assets across 9 years of filings, most recently posting $10.3 million for Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $10.3 million, up 441.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.3 million (up 441.68% YoY), and the FY2025 annual result was $10.3 million, changed 0.0% from the prior year.
• Other Non-Current Assets came in at $10.3 million for Q1 2026 at Allogene Therapeutics, roughly flat from $10.3 million in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $10.3 million in Q3 2022 to a low of $1.9 million in Q1 2025.
• The 5-year median for Other Non-Current Assets is $10.3 million (2022), against an average of $9.0 million.
• Across the five-year window, Other Non-Current Assets plunged 63.17% in 2025 and jumped 441.68% in 2026, its largest moves.
• Allogene Therapeutics' Other Non-Current Assets stood at $10.3 million in 2022, then tumbled by 35.83% to $6.6 million in 2023, then jumped by 55.84% to $10.3 million in 2024, then changed by 0.0% to $10.3 million in 2025, then changed by 0.0% to $10.3 million in 2026.
• The last three Other Non-Current Assets figures came in at $10.3 million (Q1 2026), $10.3 million (Q4 2025), and $10.3 million (Q3 2025), per Business Quant data.